Skip to main content

Table 2 Parameter estimates describing lumefantrine population pharmacokinetics for HIV-malaria co-infected patients treated with artemether-lumefantrine

From: The influence of nevirapine and efavirenz-based anti-retroviral therapy on the pharmacokinetics of lumefantrine and anti-malarial dose recommendation in HIV-malaria co-treatment

Parameters Description Estimates (95% CI) BSV (RSE %) (Shrinkage %) BOV (RSE %) (Shrinkage %)
Ka (hr-1) Absorption rate constant 0.032 (0.029-0.034) 29% (18) (30)  
Vc/F (liters) Central volume 25.6 (16.21-34.99) 82% (24) (51)  
CL/F (liters/hr) Clearance 4.54 (3.913-5.167) 0* 19% (22) (44)
Q/F (liters/hr) Inter-compartmental exchange Clearance 1.23 (0.99-1.47) 27% (24) (23)  
Vp/F (liters) Peripheral Volume 203 (167.13-238.87) 39% (22) (37)  
t lag (hr) Absorption lag time 1.45 (1.25-1.65 ) 0*  
F1 Bioavailability (population typical value) 1* 47% (11) (5)  
F1 EFV Relative bioavailability for patients on Efavirenz 0.42 (0.34-0.5)   
F1 NEV Relative bioavailability for patients on Nevirapine 1.32 (1.08-1.52)   
ADD Additive residual error 26.30 (4.15-48.44)   
PROP Proportion residual error 0.083 (0.06-0.10)   
  1. RSE, relative standard error; CI, confidence intervals; BSV, Between Subject Variability; BOV, Between Occasion Variability; *,Fixed to this value.